Here are relevant reports on : asia-pacific-oncology-drugs-market
-
Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (Anti–Epileptic Drugs,Anti–Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029
The global therapeutic drug monitoring market, valued at US$2.14 billion in 2023, stood at US$2.30 billion in 2024 and is projected to advance at a resilient CAGR of 8.4% from 2024 to 2029, culminating in a forecasted valuation of US$3.44 billion by the end of the period. This growth is brought on by a number of causes, such as the rise in chronic diseases like cancer, heart disease, epilepsy, and autoimmune conditions.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) - Global Forecast to 2026
The global cognition enhancement market is expected to grow from USD 23.4 billion in 2021 to USD 38.9 billion by 2026, at a compound annual growth rate (CAGR) of 10.7% during the forecast period.The leading players Eisai Co., Ltd. (Japan), Johnson & Johnson Services, Inc. (US), Biogen Inc. (US), Eli Lilly and Company (US), Nordic Naturals (US), Natrol, LLC (US), Cambridge Cognition Ltd. (UK), and Cogstate Ltd. (US).
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Angiographic Catheters Market by Application (Coronary, Endovascular, Neurology and Oncology), Geography (North America, Europe, Asia Pacific and Row), End-User Analysis (Reusage Scenario, Purchase Pattern) and Competitive Scenario - Global Forecast to 2022
Angiographic catheters market is expected to reach USD 1,402.8 million by 2022 from USD 922.1 million in 2016 and, at a CAGR of 7.4%. The base year for this study is 2016 and the forecast period is 2017–2022. Increasing number of Cath labs in APAC, incidences of CVDs and preference for minimally invasive surgeries are few of the reasons for the growth of this market
- Published: April 2018
- Price: $ 4950
- TOC Available:
-
Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium–201(Tl-201), gallium–67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.
- Published: May 2013
- Price: $ 4950
- TOC Available:
-
mRNA Therapeutics Market by Product (Vaccines, Drugs), Application (Oncology, Rare Diseases, Infectious Diseases, Other Applications), End User (Hospitals & Clinics, Research Settings) - Global Forecast to 2027
The global mRNA therapeutics market is projected to reach USD ~35 billion by 2027 from USD 32 billion in 2022, at a CAGR of ~2% between 2022 and 2027.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Software-as-a-Service (SaaS) Market in Asia-Pacific (APAC)
The APAC Software as a Service (SaaS) market is expected to grow from $390 million in 2008 to $4321 million in 2015, at an estimated CAGR of 41.0% from 2008 to 2015. The appeal and reach of software as a service (SaaS) continue to grow rapidly among enterprises in Asia Pacific.
- Published: February 2011
- Price: $ 4950
- TOC Available:
-
Global Weight Loss Drugs, Supplements And Cosmetics Market
Individuals with high BMI have a greater risk of developing diseases such as cancer and diabetes. This holds true for both men and women; and those with BMI above 35 are at the highest risk. However, increasing awareness about obesity is encouraging consumers to seek medical assistance and consultation for weight reduction. The market for weight-loss drugs, cosmetics, and supplements is witnessing a significant growth as these do not involve strict diet or exercise regimens. Top pharmaceutical companies have thus increased R&D investments for anti-obesity drugs with minimal or no side effects.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
BRIC Diabetes Drugs Market (2010-2015) in Brazil, Russia, India, China
The prevalence of diabetes is increasing globally with the increase in life expectancy and rising incidence of obesity. Brazil’s diabetes drugs market is showing a double digit growth rate; while the Russian insulin market is also expected to witness significant growth with an estimated over 20 million patients in the region requiring diabetes treatment by 2025. India and China have the highest number of diabetics in the world – China alone is expected to have more than 71 million diabetic patients by 2025; and the similarly huge patient-base in India has already attracted a number of pharmaceutical companies such as Eli Lilly and Novo Nordisk. These companies are offering easy-to-use insulin versions to grab the market share in the Indian market for diabetes drugs. Thus, diabetes drugs market in BRIC economies is expected to have significant growth opportunities in the years to come.
- Published: April 2010
- Price: $ 4950
- TOC Available:
-
Global Breast Cancer Drugs Market
There are about one million new cases of breast cancer every year. Breast cancer accounts for about 10% of world wide cancer. There has been significant increase in awareness levels with respect to impact on survival rates incase of early diagnosis. Therefore, opening novel opportunities for breast cancer drugs market.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Global Ophthalmology Drugs & Devices Market
Global ophthalmology drug and devices market is witnessing a significant growth due to the increasing incidence and prevalence of eye related disorders such as presbyopia, macular degeneration, and diabetic retinopathy among the aging population. With the introduction of ophthalmic devices equipped with sophisticated technologies, people are increasingly opting for ophthalmic surgeries to correct their eye related disorders.
- Published: May 2010
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
